Cantini F et al. - Remission in up to 24% of patients with peripheral psoriatic arthritis (PsA), receiving anti-TNF drugs vs those treated with traditional DMARDs is more frequent, but not longer. Patients remain in remission for a long period after therapy interruption, thus suggesting an intermittent therapeutic strategy. Methods
Study to evaluate the frequency and duration of clinical remission in pts with PsA
All outpatients with peripheral PsA and RA were included in a prospective, case-control study
Primary end point was to assess the frequency of remission in peripheral PsA vs RA
Secondary end points: comparison of duration of clinical remission, ACR 20, 50, 70 RR, and any remission predictor at diagnosis
Therapy was suspended in PsA pts and controls if achieving remission
Results
One or more episodes of remission occurred in 24.1% of PsA pts and in 7.5% of controls
The mean duration of remission was of 13 ± 9.4 mos in PsA pts and 4 ± 3.7 in controls
Remission episodes were more frequent in PsA pts treated with anti-TNF vs those receiving traditional DMARDs with no differences regarding the duration
After therapy interruption, the remission duration was 12 ± 2.4 mos in PsA and 3 ± 1.5 in RA
No remission predictor at diagnosis resulted by multivariate analysis
See all
